Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy in Limited-stage Small Cell Lung Cancer
Background and objective The group of small cell lung cancer (SCLC) are usually highly sensitive to chemotherapy, and less than 15% of them are resistant to drugs. We respectively evaluate the correlation of the sequence and timing of radiotherapy with progression-free survival (PFS) and overall sur...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2016-12-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.12.11 |
| _version_ | 1828394469125259264 |
|---|---|
| author | Daquan WANG Liming XU Lujun ZHAO Wencheng ZHANG Qingsong PANG Ningbo LIU Xi CHEN Xiuli CHEN Zhiyong YUAN Ping WANG |
| author_facet | Daquan WANG Liming XU Lujun ZHAO Wencheng ZHANG Qingsong PANG Ningbo LIU Xi CHEN Xiuli CHEN Zhiyong YUAN Ping WANG |
| author_sort | Daquan WANG |
| collection | DOAJ |
| description | Background and objective The group of small cell lung cancer (SCLC) are usually highly sensitive to chemotherapy, and less than 15% of them are resistant to drugs. We respectively evaluate the correlation of the sequence and timing of radiotherapy with progression-free survival (PFS) and overall survival (OS) in patients with limited-stage SCLC (LS-SCLC), and to figure out whether concurrent chemoradiotherapy is superior to sequent chemoradiotherapy. Methods Sixty-seven patients diagnosed with LS-SCLC from January 2009 to June 2014 failed to respond to induction chemotherapy. According to the sequence of therapy, they were divided into concurrent chemoradiotherapy group (n=32) and sequent chemoradiotherapy group (n=35). Ninety-four percent of the patients were diagnosed with stage III, and six percent were stage Ib-IIb. Twenty-five patients were treated with prophylactic cranial irradiation (PCI). The Kaplan-Meier method was used to calculate survival time and Log-rank test was used for between-group comparisons. Between-group comparison of categorical data was made by χ2 test. Results In all patients, the 2-year OS, PFS and LC rates were 53.7%, 20.9% and 58.2%. The 2-year OS and PFS rates of concurrent chemoradiotherapy group and sequent chemoradiotherapy were 37.5% vs 54.3% (P=0.048) and 12.5% vs 28.6% (P=0.149). Hematologic toxicities were more common in concurrent group than sequent one (P=0.031), and no statistical difference was observed between the two groups in terms of grade 3 radiation esophagitis, pneumonitis and gastrointestinal reactions (9.4% vs 0, P=0.176; 12.5% vs 2.9%, P=0.318; 12.5% vs 2.9%, P=0.109). Patients treated with PCI have superior OS and PFS comparing with those not (56.0% vs 38.1%, P=0.029; 24% vs 19%, P=0.012). Conclusion Concurrent chemoradiotherapy with original chemotherapy regimens may not be suitable for patients who failed to respond to induction chemotherapy in LS-SCLC, and second-line regimens or radiotherapy alone can be used for them, but prospective trils with large sample are still needed to confirm that. |
| first_indexed | 2024-12-10T07:56:02Z |
| format | Article |
| id | doaj.art-6b41d94242194be3b6525b267c152664 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-10T07:56:02Z |
| publishDate | 2016-12-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-6b41d94242194be3b6525b267c1526642022-12-22T01:56:54ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872016-12-01191287187810.3779/j.issn.1009-3419.2016.12.11Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung CancerDaquan WANG0Liming XU1Lujun ZHAO2Wencheng ZHANG3Qingsong PANG4Ningbo LIU5Xi CHEN6Xiuli CHEN7Zhiyong YUAN8Ping WANG9Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaDepartment of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, ChinaBackground and objective The group of small cell lung cancer (SCLC) are usually highly sensitive to chemotherapy, and less than 15% of them are resistant to drugs. We respectively evaluate the correlation of the sequence and timing of radiotherapy with progression-free survival (PFS) and overall survival (OS) in patients with limited-stage SCLC (LS-SCLC), and to figure out whether concurrent chemoradiotherapy is superior to sequent chemoradiotherapy. Methods Sixty-seven patients diagnosed with LS-SCLC from January 2009 to June 2014 failed to respond to induction chemotherapy. According to the sequence of therapy, they were divided into concurrent chemoradiotherapy group (n=32) and sequent chemoradiotherapy group (n=35). Ninety-four percent of the patients were diagnosed with stage III, and six percent were stage Ib-IIb. Twenty-five patients were treated with prophylactic cranial irradiation (PCI). The Kaplan-Meier method was used to calculate survival time and Log-rank test was used for between-group comparisons. Between-group comparison of categorical data was made by χ2 test. Results In all patients, the 2-year OS, PFS and LC rates were 53.7%, 20.9% and 58.2%. The 2-year OS and PFS rates of concurrent chemoradiotherapy group and sequent chemoradiotherapy were 37.5% vs 54.3% (P=0.048) and 12.5% vs 28.6% (P=0.149). Hematologic toxicities were more common in concurrent group than sequent one (P=0.031), and no statistical difference was observed between the two groups in terms of grade 3 radiation esophagitis, pneumonitis and gastrointestinal reactions (9.4% vs 0, P=0.176; 12.5% vs 2.9%, P=0.318; 12.5% vs 2.9%, P=0.109). Patients treated with PCI have superior OS and PFS comparing with those not (56.0% vs 38.1%, P=0.029; 24% vs 19%, P=0.012). Conclusion Concurrent chemoradiotherapy with original chemotherapy regimens may not be suitable for patients who failed to respond to induction chemotherapy in LS-SCLC, and second-line regimens or radiotherapy alone can be used for them, but prospective trils with large sample are still needed to confirm that.http://dx.doi.org/10.3779/j.issn.1009-3419.2016.12.11Lung neoplasmsInduction chemotherapyConcurrent chemoradiotherapySecond-line regimensPrognosis |
| spellingShingle | Daquan WANG Liming XU Lujun ZHAO Wencheng ZHANG Qingsong PANG Ningbo LIU Xi CHEN Xiuli CHEN Zhiyong YUAN Ping WANG Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy in Limited-stage Small Cell Lung Cancer Chinese Journal of Lung Cancer Lung neoplasms Induction chemotherapy Concurrent chemoradiotherapy Second-line regimens Prognosis |
| title | Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer |
| title_full | Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer |
| title_fullStr | Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer |
| title_full_unstemmed | Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer |
| title_short | Concurrent Chemoradiotherapy with Original Chemotherapy Regimens may not be Suitable for Patients Who Failed to Respond to Induction Chemotherapy
in Limited-stage Small Cell Lung Cancer |
| title_sort | concurrent chemoradiotherapy with original chemotherapy regimens may not be suitable for patients who failed to respond to induction chemotherapy
in limited stage small cell lung cancer |
| topic | Lung neoplasms Induction chemotherapy Concurrent chemoradiotherapy Second-line regimens Prognosis |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2016.12.11 |
| work_keys_str_mv | AT daquanwang concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT limingxu concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT lujunzhao concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT wenchengzhang concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT qingsongpang concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT ningboliu concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT xichen concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT xiulichen concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT zhiyongyuan concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer AT pingwang concurrentchemoradiotherapywithoriginalchemotherapyregimensmaynotbesuitableforpatientswhofailedtorespondtoinductionchemotherapyinlimitedstagesmallcelllungcancer |